Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Apr 13;3(5):399-403.
doi: 10.1002/acn3.309. eCollection 2016 May.

Plasma neuronal exosomal levels of Alzheimer's disease biomarkers in normal aging

Erin L Abner  1 , Gregory A Jicha  2 , Leslie M Shaw  3 , John Q Trojanowski  4 , Edward J Goetzl  5
Affiliations

Plasma neuronal exosomal levels of Alzheimer's disease biomarkers in normal aging

Erin L Abner et al. Ann Clin Transl Neurol. .

Abstract

Plasma neuronal exosomal levels of pathogenic Alzheimer's disease (AD) proteins, cellular survival factors, and lysosomal proteins distinguish AD patients from control subjects, but changes in these exosomal proteins associated with normal aging have not been described for cognitively intact subjects. Plasma neuronal exosomal levels of P-T181-tau, P-S396-tau, Aβ 1-42, cathepsin D, repressor element 1-silencing transcription factor, and neurogranin were quantified longitudinally in cognitively intact older adults using two samples collected at 3- to 11-year intervals. Except for P-S396-tau, exosomal protein levels changed significantly with aging, but were largely outside the range observed in AD patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Levels of plasma exosomal proteins in age‐ and sex‐matched cognitively intact subjects (CIS) and patients with Alzheimer's disease(AD).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. O'Bryant SE, Gupta V, Henriksen K, et al. Guidelines for the standardization of preanalytic variables for blood‐based biomarker studies in Alzheimer's disease research. Alzheimers Dement 2015;11:549–560. - PMC - PubMed
    1. Russo I, Bubacco L, Greggio E. Exosomes‐associated neurodegeneration and progression of Parkinson's disease. Am J Neurodegener Dis 2012;1:217–225. - PMC - PubMed
    1. Marzesco AM, Janich P, Wilsch‐Brauninger M, et al. Release of extracellular membrane particles carrying the stem cell marker prominin‐1 (CD133) from neural progenitors and other epithelial cells. J Cell Sci 2005;118:2849–2858. - PubMed
    1. Bellingham SA, Guo BB, Coleman BM, et al. Exosomes: vehicles for the transfer of toxic proteins associated with neurodegenerative diseases? Front Physiol 2012;3:124. - PMC - PubMed
    1. Fiandaca MS, Kapogiannis D, Mapstone M, et al. Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: a case‐control study. Alzheimers Dement 2015;11:600–607. - PMC - PubMed